Literature DB >> 15324779

Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET.

Anthony K P Jones1, Hiroshi Watabe, Vin J Cunningham, Terry Jones.   

Abstract

Central neuropathic pain (CNP) is pain resulting from damage to the central nervous system. Up till now, it has not been possible to identify a common lesion or pharmacological deficit in these patients. This preliminary study in a group of patients with CNP with predominantly post-stroke pain, demonstrates that there is significantly less opioid receptor binding in a number of cortical and sub-cortical structures that are mostly, but not exclusively, within the medial pain system in patients compared to age-matched pain-free controls. The reductions in opioid receptor binding within the medial system were observed mainly in the dorsolateral (Brodman area 10) and anterior cingulate (Brodman area 24 with some extension into area 23) and insula cortices and the thalamus. There were also reductions in the lateral pain system within the inferior parietal cortex (Brodman area 40). These changes in binding could not be accounted for by the cerebral lesions shown by CT or MRI, which were outside the areas of reduced binding and the human pain system. To our knowledge this is the first systematic demonstration of a reduction in opioid receptor-binding capacity in neurones within the human nociceptive system in patients with CNP. This may be a key common factor resulting in undamped nociceptor activity within some of the structures that are predominantly within the medial nociceptive system. If confirmed, these findings may explain why certain patients with CNP require high doses of synthetic opiates to achieve optimum analgesia. The findings also raise the possibility of new pharmacological approaches to treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324779     DOI: 10.1016/j.ejpain.2003.11.017

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  37 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

2.  Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans.

Authors:  Irene Tracey
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

3.  Alterations in endogenous opioid functional measures in chronic back pain.

Authors:  Ilkka K Martikainen; Marta Peciña; Tiffany M Love; Emily B Nuechterlein; Chelsea M Cummiford; Carmen R Green; Richard E Harris; Christian S Stohler; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

Review 4.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

Review 5.  Experimental designs and brain mapping approaches for studying the placebo analgesic effect.

Authors:  Luana Colloca; Fabrizio Benedetti; Carlo Adolfo Porro
Journal:  Eur J Appl Physiol       Date:  2007-10-25       Impact factor: 3.078

Review 6.  Role of neuroimaging in analgesic drug development.

Authors:  Jane Lawrence; Sean C Mackey
Journal:  Drugs R D       Date:  2008

Review 7.  Predictive mechanisms linking brain opioids to chronic pain vulnerability and resilience.

Authors:  Anthony Kenneth Peter Jones; Christopher Andrew Brown
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

Review 8.  Cerebral cortex modulation of pain.

Authors:  Yu-feng Xie; Fu-quan Huo; Jing-shi Tang
Journal:  Acta Pharmacol Sin       Date:  2008-12-15       Impact factor: 6.150

Review 9.  Cognitive and emotional control of pain and its disruption in chronic pain.

Authors:  M Catherine Bushnell; Marta Ceko; Lucie A Low
Journal:  Nat Rev Neurosci       Date:  2013-05-30       Impact factor: 34.870

Review 10.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.